<DOC>
	<DOCNO>NCT00900757</DOCNO>
	<brief_summary>1 . Purpose objective : 1 . To determine safety tolerability palonosetron prevention radiation induce nausea vomiting ( RINV ) primary glioma patient receive radiation ( RT ) concomitant temozolomide ( TMZ ) . 2 . To determine efficacy palonosetron primary glioma patient receive six week RT concomitant TMZ 3 . To evaluate effect palonosetron quality life primary glioma patient receive six week RT Concomitant TMZ . 2 . Study activity Population group : We conduct phase II single arm trial Palonosetron ( PALO ) prevention RINV primary malignant glioma patient receive radiation therapy ( RT ) concomitant temozolomide ( TMZ ) . All eligible patient receive plan total dose 54-60 GY radiation 75 mg/m2 daily temozolomide total six week treatment . For week radiation patient receive single 0.25 mg intravenous dose palonosetron 30 minute week radiation fraction . This schedule repeat week radiation total 6 week . Forty subject gliomas participate . 3 . Data analysis risk/safety issue : The frequency toxicity summarize type severe grade experience . The complete response rate , define proportion patient emetic episode use rescue medication receive radiation concomitant temozolomide , estimate 95 % confidence interval .</brief_summary>
	<brief_title>Intravenous Palonosetron With Radiotherapy Concomitant Temozolomide</brief_title>
	<detailed_description>We conduct phase II single arm trial Palonosetron ( PALO ) prevention RINV primary malignant glioma patient receive radiation therapy ( RT ) concomitant temozolomide ( TMZ ) . All eligible patient receive plan total dose 54-60 GY radiation 75 mg/m2 daily temozolomide total six week treatment . For week radiation patient receive single 0.25 mg intravenous dose palonosetron approximately 30 minute week radiation fraction . This schedule repeat week radiation total 6 week . After start radiation type rescue medication investigator 's discretion ( however give result recent publish phase II study Navari et . al . recommend use olanzapine rescue medication ) . All patient give write informed consent .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<criteria>Age ≥ 18 year ; Karnofsky ≥ 60 % ; Hematocrit &gt; 29 % , absolute neutrophil count ( ANC ) &gt; 1,000 cells/*1 , platelet &gt; 100,000 cells/*I ; Serum creatinine &lt; 1.4 mg/dl ; serum glutamate oxaloacetate transaminase ( SGOT ) bilirubin &lt; 1.5 time upper limit normal ; For patient corticosteroid , must stable dose 1 week prior entry , dose escalated entry dose level , clinically possible ; Signed informed consent approve Institutional Review Board prior patient entry ; If sexually active , patient w8ill take contraceptive measure duration treatment . Pregnancy breastfeeding ; Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid ; Inability unwillingness cooperate study procedure ; Prophylactic medication prevention nausea vomit 24 hour prior start radiation therapy full course radiation therapy prohibit , exception study drug . Corticosteroids allow treatment cerebral swelling . Rescue medication treatment nausea vomit permit radiation therapy discretion investigator . The agent , dose , time administration record patient diary ; Previous participation clinical trial involve palonosetron ; Any vomiting , retch , NCI Common Toxicity Criteria version 3.0 grade 24 nausea 24 hour precede radiation chemotherapy ; Ongoing vomit organic etiology ; Will receive radiotherapy upper abdomen within one week prior study ; Received palonosetron within 14 day prior study enrollment ; Prior Concomitant Medications Prevention/Treatment Nausea Vomiting ; Prior Concomitant Cancer Chemotherapy Radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Primary Glioma</keyword>
	<keyword>Palonosetron</keyword>
	<keyword>Standard Radiotherapy</keyword>
	<keyword>Temozolomide</keyword>
</DOC>